Hunter SyndromeWith BTI designating Hunter Syndrome as its lead xB3 candidate for clinical trials with expectation of initiation of human trials just over one year from now that could speak to how the relationship with Chiesi is progressing. With Hunter Syndrome as its lead BTI is going head-to-head against Denali which already has Hunter Syndrome in human clinical trials. BTI also has Gaucher's Disease in development with Oxyrane which is the most common Lysosomal Storage Disorder. From Hunter Syndrome, to Gaucher's Disease, to Chiesi Lysosomal Storage Disorders are a strategic focus and BTI wants to go head-to-head vs. Denali.